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Abstract
Background: Streptococcus pneumoniae causes substantial morbidity and mortality among children. The introduction
of pneumococcal conjugate vaccines (PCV) has the potential to dramatically reduce disease burden. As with any
vaccine, it is important to evaluate PCV impact, to help guide decision-making and resource-allocation. Measuring
PCV impact can be complex, particularly to measure impact on one of the most common and significant diseases
caused by the pneumococcus, namely pneumonia. Here we outline the protocol developed to evaluate the impact of
13-valent PCV (PCV13) on childhood pneumonia in Mongolia, and a number of lessons learned in implementing the
evaluation that may be helpful to other countries seeking to undertake pneumonia surveillance.
Methods: From 2016 PCV13 was introduced in a phased manner into the routine immunisation programme with
some catch-up by the Government of Mongolia. We designed an evaluation to measure vaccine impact in
children aged 2–59 months with hospitalised radiological pneumonia as a primary outcome, with secondary
objectives to measure impact on clinically-defined pneumonia, nasopharyngeal carriage of S. pneumoniae among
pneumonia patients and in the community, and severe respiratory infection associated with RSV and/or influenza. We
enhanced an existing hospital-based pneumonia surveillance system by incorporating additional study components
(nasopharyngeal swabbing using standard methods, C-reactive protein, risk factor assessment) and strengthening
clinical practices, such as radiology as well as monitoring and training. We conducted cross-sectional community
carriage surveys to provide data on impact on carriage among healthy children.
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Discussion: Establishing a robust surveillance system is an important component of monitoring the impact of PCV
within a country. The enhanced surveillance system in Mongolia will facilitate assessment of PCV13 impact on
pneumonia, with radiological confirmed disease as the primary outcome. Key lessons arising from this evaluation
have included the importance of establishing a core group of in-country staff to be responsible for surveillance
activities and to work closely with this team; to be aware of external factors that could potentially influence
disease burden estimates; to be flexible in data collection processes to respond to changing circumstances
and lastly to ensure a consistent application of the pneumonia surveillance case definition throughout the study period.
Keywords: Streptococcus pneumoniae, Pneumococcal conjugate vaccine, Mongolia, Nasopharyngeal carriage, Pneumonia,
Surveillance, Vaccine impact evaluation
Background
Streptococcus pneumoniae (the pneumococcus) is a
major cause of illness and mortality among children
worldwide, causing otitis media, meningitis, and pneu-
monia [1]. Pneumococcal conjugate vaccines (PCV) are
widely used in high-income countries, and in recent
years there has been increased introduction among
low- and middle-income countries (LMICs).
With any new vaccine introduction, countries seek evi-
dence of PCV impact in their own population to guide
decision-making and allocation of limited health re-
sources. In assessing the impact of PCV, many countries
have used invasive pneumococcal disease (IPD) as the
primary endpoint [2–7], however this endpoint can be
relatively rare. In such settings, large impact studies
(usually in the tens of thousands) are needed to account
for year-to-year variation in case numbers and changes
in serotype distribution. IPD relies on robust sample col-
lection (prior to antibiotic use) and diagnostic clinical
microbiology capacity, which is often not available in
resource-limited settings. Moreover, restricting the
evaluation of PCV impact to IPD misses the opportunity
to measure vaccine impact on non-bacteraemic pneu-
monia, one of the most common and significant illnesses
caused by the pneumococcus.
Pneumonia is the most common cause of childhood
death globally. Pneumococcal pneumonia contributes
substantially to the most severe and often fatal forms of
pneumonia [8]. There are few data on the impact of
PCV on pneumonia in LMICs, due in part to inherent
challenges in diagnosing pneumonia and establishing a
cause-specific aetiology.
Nasopharyngeal pneumococcal carriage is a precursor
to pneumococcal disease [9]. PCVs reduce vaccine-type
(VT) serotype carriage while overall pneumococcal car-
riage is only slightly decreased or unchanged due to
serotype replacement. Serotype replacement has been
documented following the introduction of PCV [10, 11]
and it is critical to consider and monitor as part of
long-term vaccine impact. Isolating a pneumococcus
from a nasopharyngeal swab in a child with pneumonia
does not necessarily indicate a pneumococcal aetiology.
However a reduction in the detection of VT serotypes
over time will reflect vaccine effectiveness in prevent-
ing pneumococcal pneumonia episodes due to those
serotypes [12].
Mongolia is a land-locked country in Central Asia.
Nearly half of its 3 million people live in the capital,
Ulaanbaatar, with the remainder being dispersed over a
vast geographic area. In Mongolia, pneumonia is one of
the most common causes of mortality among children,
accounting for 25% of deaths among children under the
age of 5 outside of the neonatal period [13]. The
Government of Mongolia (GoM) decided to introduce
the 13-valent PCV (PCV13) and to monitor its impact.
A collaboration was established between the GoM, the
World Health Organization (WHO) and the Murdoch
Children’s Research Institute (MCRI) to evaluate the im-
pact of PCV introduction in Mongolia. In the context of
relatively low rates of culture-confirmed IPD, and an
existing hospital-based surveillance system enrolling
cases of pneumonia, we selected pneumonia as the pri-
mary endpoint. Here we describe the methodological ap-
proach taken to develop prospective hospital-based
surveillance for measurement of vaccine impact on
pneumonia, the use of community carriage surveys and
some of the key challenges and lessons learnt in this on-
going surveillance programme. We believe that this in-
formation will benefit other resource-limited countries
seeking to establish pneumonia surveillance for the
measurement of vaccine impact.
Evaluation objectives
An evaluation plan was developed to use enhanced
hospital-based pneumonia surveillance to document the
impact of PCV on hospitalised pneumonia in children
aged 2–59months, and cross-sectional carriage surveys
of healthy children to measure vaccine impact on com-
munity carriage of pneumococci. Additionally, we will
evaluate the PCV impact on severe and very severe
lower respiratory tract infection (LRTI) cases associated
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with respiratory syncytial virus (RSV) and influenza virus
in a subset of children aged 2–23months.
This evaluation has been approved by the Human
Research Ethics committees of the Mongolian Ministry of
Health, the Royal Children’s Hospital (Melbourne) and the
World Health Organization Western Pacific Regional
Office.
Overall, there are six study objectives:
Primary objective
1) To evaluate the impact of PCV13 introduction on
the incidence of radiological pneumonia among
children aged 2–59 months
The primary endpoint was selected to capture the
major burden of pneumococcal disease, pneumonia,
using a standardised WHO definition of radiological
pneumonia with increased specificity compared to other
pneumonia classifications [14]. In previous clinical trials,
radiological pneumonia best discriminated between PCV
vaccinated and control groups [15–18], likely due to a
higher proportion of pneumococcal cases. An effective
PCV program will therefore have a greater impact on
this endpoint.
Secondary objectives
2) To evaluate the impact of PCV13 introduction on
the incidence of severe and very severe pneumonia in
children aged 2–59 months
To measure the full impact of PCV13 on pneumo-
nia the impact on clinical parameters including
severe and very severe pneumonia will also be
assessed. Although this outcome can lack specificity,
it is relevant for settings where childhood pneumo-
nia is diagnosed on clinical parameters, usually based
on the presence of cough and raised respiratory rate.
Importantly, a randomised controlled trial in The
Gambia, evaluating three doses of 9-valent PCV in
infants showed a vaccine efficacy of 7% (95% confi-
dence interval (CI) 1–12) against clinical pneumonia,
and 12% efficacy (95% CI -9-29) against severe clin-
ical pneumonia (using the earlier Integrated Manage-
ment of Childhood Illness [IMCI] definition, which
included chest indrawing as a sign of severe pneu-
monia) [19].
3) To evaluate the impact of PCV13 introduction on
the incidence of definite or probable pneumococcal
pneumonia in children aged 2–59 months
In young children, definitive diagnosis of pneumococ-
cal pneumonia is rare, as they do not produce sputum,
and very few pneumonia cases are bacteraemic, making
blood cultures a highly insensitive test [20]. To address
this, our study will incorporate a definition of probable
pneumococcal pneumonia [21].
Surveillance cases will undergo routine testing for
C-reactive protein (CRP), a non-specific “marker” for
disease, and nasopharyngeal swabbing, to enable an as-
sessment of vaccine impact on a subgroup of radio-
logical pneumonia patients that may be considered
either probable (elevated CRP, high density pneumococci
in the nasopharynx, pathogenic serotypes) or definite
(e.g. bacteraemic culture-positive) pneumococcal pneu-
monia cases.
4) To evaluate the impact of PCV13 on prevalence of
vaccine type (VT) and non-vaccine type (NVT)
pneumococci nasopharyngeal carriage in hospitalised
children with radiologically confirmed pneumonia
We will evaluate the change in overall, VT and NVT
carriage in hospitalised children with radiologically-con-
firmed pneumonia following PCV13 introduction. A study
conducted in Israel [22] prior to PCV introduction,
showed that children admitted with radiologically-con-
firmed pneumonia were more likely to carry certain sero-
types (1, 5, 7F, 9 V, 14, 19A and 22F) compared with
healthy controls. We will be able to detect reductions in
VT pneumococci in the nasopharynx of pneumonia pa-
tients with radiologically confirmed disease, and identify
any increases in NVTs following PCV introduction.
5) To evaluate the impact of PCV13 on prevalence of
vaccine type (VT) and non-vaccine type (NVT)
pneumococci nasopharyngeal carriage in hospitalised
children with severe clinical pneumonia
We will evaluate the change in overall, VT and NVT
carriage in hospitalised children with severe clinical
pneumonia following PCV13 introduction. Depending
on total annual pneumonia cases admitted, we may
focus on subgroups such as hypoxic children, children
who are readmitted and children with viral co-infections
for testing.
6) To evaluate the impact of PCV13 on prevalence of
VT and NVT pneumococci nasopharyngeal carriage
in the community
It is important to document the impact of PCV13 on
both VT and NVT carriage in the community. Reductions
in VT carriage in vaccinated children have been associated
with reductions in carriage at the population level [23],
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while both NVT carriage and rates of NVT invasive dis-
ease have increased [24]. Currently, data on vaccine im-
pact including serotype replacement from LMICs are
limited. In Mongolia we are conducting cross-sectional
community carriage surveys to assess nasopharyngeal
pneumococcal carriage before introduction of the vaccine
and for 2 years post-PCV13 introduction, in a sample of
healthy children aged 12–23months (eligible to be vacci-
nated) and in a sample of young infants aged 5–8 weeks
(too young to be vaccinated).
7) To evaluate the impact of PCV13 introduction on
the incidence of severe LRTI associated with RSV
and/or influenza among children aged 2–23 months.
RSV and influenza, like the pneumococcus, are im-
portant causes of childhood pneumonia globally, espe-
cially in children less than 2 years of age [25, 26].
Although the interaction between these two viruses and
S. pneumoniae has been described using in vitro and
animal models, clinical data on the impact of PCV on
the burden of RSV and/or influenza infections is still
scarce. To date only two studies explored the association
between PCV use and RSV or influenza infections: a
retrospective time series analysis of US hospitalisation
data comparing pre- (1992/1993) and post-PCV7 (2008/
2009) data [27] and a double-blind, randomized, placebo
controlled trial in South Africa exploring the impact of
the 9-valent PCV on viral-associated pneumonia [28].
These data suggest a beneficial effect of PCV on pneu-
monia associated with viruses. The impact of PCV13 on
pneumonia associated with RSV and influenza in young
children needs to be explored further, particularly in
LMICs, where the benefit may be greater given the
higher rates of disease and severity.
For this endpoint we use the WHO definition for a se-
vere LRTI case (defined as an acute illness associated
with cough or breathing difficulty and fast breathing (re-
spiratory rate > 50) and arterial oxygen saturation (SaO2)
less than 93% [29]) and polymerase chain reaction (PCR)
detection of RSV or influenza virus from a nasopharyn-
geal swab.
Research setting
Mongolia has a very well-structured health system with
accurate data on the number of under-5 children in
every district. The vast majority of healthcare for chil-
dren is provided through the public health system with
few children accessing the private sector. Most pneumo-
nia cases are therefore captured by the public health ser-
vices in district and tertiary care facilities. Hospital care
for children is geographically and financially accessible
in Ulaanbaatar, with inpatient care provided free of
charge for children. As such, the vast majority of cases
of severe pneumonia among age-eligible children resid-
ing in the evaluation districts will be captured by the
surveillance system. The surveillance system may thus
be considered population-based, permitting the calcula-
tion of incidence rates.
The GoM identified four of the nine districts of
Ulaanbaatar to participate in the evaluation (Songino-
khairkhan, Sukhbaatar, Chingeltei and Bayanzurkh).
These are four of the largest districts of Ulaanbaatar,
together comprising approximately 70% of the city’s
population. In 2012, there were 5903 under-5 year old
hospital admissions with a discharge diagnosis of
pneumonia in the participating districts, from an esti-
mated population of 98,433 (60 episodes per 1000
under-5 population). There is strong seasonal variation in
pneumonia incidence, with the peak season occurring in
the winter months from October until April. Eighty per-
cent (n = 4772) of the 5903 pneumonia cases admitted in
2012 occurred during these 7months.
The GoM is introducing PCV13 in a phased manner.
This approach is consistent with the standard approach
taken to new vaccine implementation in the country,
and also facilitates rigorous evaluation of impact by
allowing for contemporaneous comparison of vaccinated
and unvaccinated populations, rather than relying on be-
fore and after comparisons alone. The first phase of
PCV13 introduction in two of the evaluation districts
(Songinokhairkhan and Sukhbaatar, termed “Phase 1 dis-
tricts”) commenced at the start of June 2016 (Table 1),
followed by stepped introduction in the remaining evalu-
ation districts (“Phase 2 districts”). PCV13 was intro-
duced into one Phase 2 district (Bayanzurkh) in June
2017, with introduction into the second Phase 2 district
(Chingeltei) and other districts of Ulaanbaatar from
March 2018.
PCV13 was implemented as a three-dose schedule,
with doses given to infants at two, four and 9 months of
age. There was a three-month catch-up campaign at the
time of vaccine introduction in 2016 and 2017 in each
of the evaluation districts for children up to 23months
of age, who were given two doses of PCV13 (2 months
apart) to maximise vaccine impact, alongside vaccine
introduction in 2016 and 2017. In 2018 vaccine intro-
duction into Chingeltei and the remaining districts of
Ulaanbaatar was done without a catch-up component.
Materials and methods
Enhanced hospital-based surveillance of pneumonia in
children aged 2–59months
At the time that evaluation data collection systems were
being established, a surveillance system for meningitis,
sepsis and pneumonia was in place in most district hos-
pitals in Ulaanbaatar, as part of the WHO-supported In-
vasive Bacterial Vaccine Preventable Disease (IB-VPD)
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Surveillance Network initiated in 2007. Under this sys-
tem, all patients older than 59 days and less than 5 years
of age admitted to a participating hospital with sus-
pected meningitis, pneumonia or sepsis are enrolled.
Hospital staff members identify admissions that meet
the surveillance case definitions, complete a standard
case report form (CRF) and collect relevant specimens.
Blood cultures are routinely performed in all suspect
cases of pneumonia and sepsis. In cases of suspected
meningitis, cerebrospinal fluid culture is also performed.
Isolates of H. influenzae and pneumococci identified
through this surveillance system are serotyped. The
incidence of IPD as estimated through this surveillance
was approximately 20/100,000 children/year. Data on
respiratory-related IPD cases will continue to be col-
lected throughout the evaluation; however based on
the low rates of invasive respiratory disease pre-vac-
cination the likelihood of documenting any meaning-
ful impact is very small, hence it is excluded from the
study objectives.
Five hospitals are participating in the evaluation, in-
cluding one district hospital in each of the four districts,
plus the tertiary level referral hospital that receives
paediatric admissions from across the country, the
National Centre for Maternal and Child Health. All five
hospitals participating in the PCV impact evaluation are
IB-VPD surveillance sites.
From 1st April 2015, the IB-VPD system was en-
hanced in the five evaluation hospitals to enable evalu-
ation of the impact of PCV13 introduction on
pneumonia. The modifications included the following:
Case report form
The PCV13 evaluation system CRF expanded on the
IB-VPD CRF. The IB-VPD CRF included information on
presenting symptoms and signs, previous medication,
immunisation history, specimens collected and treatment
received. The enhanced surveillance added questions on
oxygen saturation and therapy, and an additional risk fac-
tor questionnaire.
Radiology data
The IB-VPD system is primarily a laboratory network,
and hence in the Mongolian IB-VPD system there was
not a strong focus on documenting radiology findings
for pneumonia cases. If done, radiographic findings were
recorded on the surveillance CRF, but films were not
retained by the hospital or available to the surveillance
system. Fluoroscopy was preferred to x-rays in many of
the facilities in Ulaanbaatar, due to the high cost of
printing x-ray films. To enhance the surveillance system
for the measurement of vaccine impact on radiological
pneumonia, there was a major focus on strengthening
and standardising the collection and archiving of chest
radiographs for all pneumonia cases. This included de-
livery of training to radiologists and radiographers in
current global standards for paediatric chest radiology.
Systems and equipment were established to enable ra-
diographs to be digitised and stored for re-reading ac-
cording to the standardised WHO criteria.
Pneumococcal carriage and viral testing
We added nasopharyngeal sampling as part of the en-
hanced surveillance. A nasopharyngeal swab is collected
from all pneumonia cases who consent, to investigate
the presence of pneumococci using lytA real-time quan-
titative PCR (qPCR) [30] and molecular serotyping by
DNA microarray. Microarray is the most sensitive
method for pneumococcal carriage studies [31]. To-
gether, this approach provides quantitative data on all
pneumococcal serotypes present within a sample. Add-
itionally, validated qPCR testing for influenza and RSV
is performed on selected severe LRTI cases [32–35].
Additional blood for CRP testing
The volume of blood taken from pneumonia admissions
was increased to be used for CRP testing. At the time
that blood is collected for culture (1–6 ml), an additional
0.5 ml of blood is taken in a serum-separating tube and
sent for testing at the National Center of Communicable
Diseases (NCCD) laboratory.
More specific surveillance case definition
The case definition applied in the pre-existing
WHO-supported system was highly sensitive, with all
children aged 1–4 years eligible for surveillance if they
had a respiratory rate of 40 or more breaths per minute.
However, many of these patients were not true cases of
Table 1 Evaluation timeline
Phase 1 districts Phase 2 districts
Songinokhairkhan and Sukhbaatar Bayanzurkh Chingeltei
April 2015 Enhanced surveillance commences
14 months pre-vaccine surveillance 26 months pre-vaccine surveillance 35months pre-vaccine surveillance
June 2016 Vaccination commences
July 2017 Vaccination commences
March 2018 Vaccination commences
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pneumonia. To reduce the workload for clinicians, and
thus make it more feasible for all eligible pneumonia pa-
tients to be enrolled with complete data, a more specific
case definition was required. Importantly, a more spe-
cific case definition also increases the likelihood of being
able to measure vaccine impact, by removing cases un-
likely to be due to pneumococcus. Under the new case
definition, a case (regardless of age) would have a re-
spiratory rate of 50 or more breaths per minute. This
cut-off has a higher specificity than the 40 or more
breaths cut-off [36].
Review of a sample of medical records revealed that a
number of children had low oxygen saturation without
an elevated respiratory rate. Given the importance of
hypoxia as a sign of severe pneumonia, this represented
a small but important group to capture in the surveil-
lance system. Children with oxygen saturation less than
90%, irrespective of respiratory rate, were thus also con-
sidered eligible for enrolment into the surveillance.
The original and the modified surveillance case defini-
tions are outlined in Table 2.
The revision to the surveillance case definition did not
alter the clinical management of patients.
Standardised recording of clinical signs
Clinicians from all hospitals participated in multiple re-
fresher training sessions on the standardised recording
and collection of clinical signs (for example, counting re-
spiratory rate for a full minute), to reduce inter-observer
and inter-hospital differences in approach. Standardised
pulse oximeters with paediatric sensors were provided to
all participating hospitals to enable accurate measure-
ment and recording of oxygen saturation.
Collection of risk factor information
An additional questionnaire collecting information on
risk factors for carriage and disease, including household
crowding, household smoke, number and PCV13 status
of other young children in the house, and breastfeeding,
was introduced.
Strengthening engagement with hospital surveillance teams
A dedicated surveillance team was established in each
hospital, including key medical and nursing staff, repre-
sentation from the hospital management, laboratory
managers and hospital epidemiologists. This team over-
sees the coordination of surveillance in the hospital and
is the liaison point for the PCV impact evaluation team.
Hospital teams have regular (at least monthly) meetings
with the PCV impact evaluation team. PCV impact
evaluation team members also visit the sites weekly to
monitor completeness of enrolments and completeness
of data on CRFs. The PCV impact evaluation team in-
cludes a Principal Investigator, Epidemiologist, Project
manager, Data manager and Laboratory manager.
With enhanced surveillance commencing in April
2015 and Phase 1 districts commencing vaccination in
June 2016 we have been able to collect strong baseline
data, with 14 months of enhanced surveillance pre-vac-
cine data prior to PCV13 introduction into these dis-
tricts, and prospective collection of over 2 years of
pre-vaccine enhanced surveillance data in the Phase 2
districts. Enhanced surveillance data will be collected for
a minimum of 2 years from vaccine introduction into
Phase 1 districts.
Case identification and enrolment
Hospital doctors working in the admissions area of each
hospital have been trained on the surveillance proce-
dures, including application of the modified case defin-
ition and informed consent. Every child aged 2–59
months who is admitted with suspected pneumonia is
assessed by a hospital doctor to determine whether they
meet the surveillance case definition. Any child meeting
the case definition is allocated a unique surveillance
identification number and enrolled into the surveillance
system. Children re-admitted within 14 days after a pre-
vious pneumonia admission and children residing out-
side the four evaluation districts are not eligible for
enrolment into the enhanced surveillance.
Table 2 Pneumonia surveillance case definitions
Surveillance case definition in use in the WHO-supported system Revised case definition introduced at commencement of enhanced system
Any child aged 2–59 months admitted to a hospital
conducting surveillance, demonstrating:
A child (aged 2–59 months) is eligible for surveillance
if they meet any one of the following:
cough OR difficulty breathing
AND EITHER
displaying fast breathing when calm (as defined by age):
• > = 50 breaths per minute in infants aged 2–12months
• > = 40 breaths per minute in children aged 1–4 years
cough OR difficulty breathing,
AND
respiratory rate > =50 bpm (all ages),
OR
oxygen saturation < 90%
OR
with a clinical diagnosis of severe pneumonia (based on the
presence of chest indrawing, stridor, or a danger sign
[inability to feed, vomiting everything, convulsions,
prostration/lethargy]).
OR
with a clinical diagnosis of severe pneumonia
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The IB-VPD system is a public health surveillance sys-
tem and as such does not require individual informed
consent. As the additional items undertaken in the en-
hanced system are to serve a research objective, and in-
clude the collection of information and specimens that
are not related to the clinical care of the patient, individ-
ual informed consent is required. The additional data
and sample collection is only undertaken if the parent or
guardian provides informed written consent.
Samples are collected as soon as possible after admis-
sion, ideally before treatment commences, and not after
72 h from time of admission. The date and time of ad-
mission and of collection of each specimen is recorded
on the CRF. If hospital treatment (for example, a dose of
antibiotics) commences prior to collection of samples,
this is also recorded on the CRF. Any patients who are
missed at time of admission are enrolled retrospectively
into the surveillance and the CRF is completed. If the
enrolment is within 72 h specimens are collected.
Specimen handling, transportation and storage
Nasopharyngeal samples are collected and stored ac-
cording to WHO guidelines [37]. Swabs are collected by
nurses trained in this technique by the PCV impact
evaluation team. After collection, nasopharyngeal swabs
are stored in a refrigerator in the specimen collection
area at each hospital. They are transported in a cool-box
to the NCCD microbiology laboratory, where they are
vortexed. Three aliquots are taken for each swab and
frozen at ultra-low temperature (ULT, − 70 °C), along
with the original sample tube, within 8 h of collection.
Two aliquots of samples are then shipped in two separ-
ate shipments on dry ice to the MCRI laboratories in
Melbourne where they are examined for pneumococcal
content by qPCR and molecular serotyping conducted
by microarray [38]. The RSV and influenza detection will
be performed at NCCD laboratories using validated
qPCR assays [32–35]. Testing for CRP is undertaken
at the NCCD laboratories, and is measured quantita-
tively using an auto-analyser (Cobas Integra 400 plus,
Roche, USA).
Data entry and management
Completed CRF and consent forms are delivered to
NCCD. All documents are checked and consent forms
are securely archived in a separate area to the CRFs.
There is direct follow up with hospitals by telephone in
the case of missing, implausible or unclear values, and if
required the CRF is returned to the hospital for correc-
tion by the relevant individual. A paper-based log of all
queried and corrected values is maintained by the PCV
impact evaluation team. An electronic register of PCV13
dose administration was developed for use in the im-
munisation clinics [39]. Information recorded on the
CRF regarding the case’s PCV13 status (ideally docu-
mented by direct reference to the patient-held immun-
isation card, or if not available by parent report) is
validated against the PCV13 immunisation database.
Conflicting records are verified against the clinic’s hard
copy immunisation record, and a log kept of any correc-
tions made.
Data are double entered into a Microsoft Access data-
base by PCV impact evaluation team personnel at
NCCD. Data checking and cleaning is undertaken jointly
between the NCCD and MCRI-based teams. Consistency
checks between the double-entered databases are per-
formed in Stata (College Station, TX, StataCorp LP) on a
monthly basis. The team investigates inconsistencies be-
tween the databases by reviewing the original source
CRF. An electronic log of all inconsistencies and correc-
tions is maintained.
Chest radiographs are digitised and uploaded to an on-
line REDCap database [40] hosted at MCRI, which is
then remotely accessible by the project radiology ex-
perts, who review according to WHO criteria and enter
the result directly into the database. Radiographs are
re-read by two radiology experts. Inter-rater reliability
will be assessed at various times during the project, with
both radiologists reviewing a random sample of images
and the results compared.
Monitoring
A number of systems have been implemented to moni-
tor completeness of enrolment and data quality.
The hospital epidemiologist reviews the paediatric ad-
missions book on a daily basis to verify how many of the
age-eligible suspected pneumonia admissions have been
enrolled into the surveillance. The medical record of
those that have not been enrolled is reviewed to verify
that the patient does not meet criteria for enrolment. A
log is kept to keep track of patients who decline consent
to participate in the enhanced surveillance.
Each hospital submits a weekly report detailing the
total number of pneumonia admissions and the propor-
tion that were enrolled in surveillance. While recognis-
ing that not all pneumonia admissions will meet the
criteria for surveillance, this statistic is an indicator that
hospitals are able to rapidly and regularly report, enab-
ling trends in enrolment to be monitored. Information is
also reported on the number of patients meeting criteria
that are not enrolled and reasons for non-enrolment.
Periodic monitoring of data on key clinical indicators
such as respiratory rate and oxygen saturation is under-
taken. Monitoring of these indicators provides insight
into whether the measurement and recording is being
done correctly. For example, clustering of recordings
around certain values, such as respiratory rates clustered
around 50 breaths per minute or oxygen saturation
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around 90%, suggests that refresher training on the
measurement of clinical signs may be required. Delays in
data entry experienced during the first year of the pro-
ject limited this component of routine monitoring to a
quarterly exercise, but thereafter it has been our aim to
produce and review these summary statistics on a
monthly basis.
To continuously monitor and enable feedback on radi-
ology quality, each week hospital radiologists provide
one or two of the films they have taken during that week
that they would consider to be of high quality. The ex-
pert radiologist reviews and provides feedback on these
films to the radiologists. The quality of the images is also
continuously assessed as part of the standardised reading
of the x-rays.
Sample size
There are expected to be about 4500 pneumonia admis-
sions among 2–59month old children meeting case
definition for surveillance annually across the four evalu-
ation districts in the absence of PCV13, of which we es-
timated 18% would be radiologically confirmed. This
equates to approximately 800 radiologically confirmed
cases per year in the four evaluation districts, an
incidence of 6 per 1000 population (based on 2015
population estimates of 124,168). A 25% reduction in
radiological pneumonia is anticipated with the introduc-
tion of PCV13. Based on the anticipated number of
radiologically confirmed admissions we will have at least
90% power to detect a significant difference in the radio-
logical pneumonia incidence rate at the 0.05 level.
Statistical analysis
The primary analysis statistic will be the radiological
pneumonia incidence rate ratio (IRR) among 2–59
month olds comparing the pre- and post-vaccine pe-
riods, using data from both the Phase 1 and Phase 2 dis-
tricts. The IRR will be estimated using a generalised
linear mixed model, with fixed effects for PCV13 intro-
duction and time period and a random effect for cluster
(district). A Poisson regression model will be used (or a
negative binomial model if there is over-dispersion), and
the logarithm of the population denominators will be in-
cluded as an offset variable. The coefficients of the
model (i.e. fixed effect for PCV13) will be exponentiated
to obtain IRRs with 95% confidence intervals. Population
denominators will be obtained from the Mongolian
Ministry of Health.
Carriage surveys among healthy children
Cross-sectional carriage surveys in the two Phase 1 dis-
tricts are undertaken in 1000 healthy children, with a
representative sample of 500 children aged 12–23
months and 500 young infants aged 5–8 weeks old. The
baseline survey was done prior to PCV13 introduction
in 2015, and a further two surveys will take place follow-
ing PCV13 introduction. Following informed consent,
risk factors for carriage are recorded, as follows: PCV13
status, breastfeeding status, type of delivery (caesarean
or vaginal), number of children aged under 5 years living
in the household, and exposure to indoor smoke from
cigarettes and stoves. A nasopharyngeal swab is taken,
transported, stored and analysed according to the same
methods used for the swabs collected from hospitalised
pneumonia patients. All surveys are conducted at the
same time and location each year, to account for any
seasonal and geographical variations.
Participant identification and enrolment
Participants are recruited from a sample of immunisa-
tion posts and health centres in the two districts that
were first to introduce PCV13. Sites were randomly
chosen to be representative of the socio-economic
spread across the different sub-districts in each of the
Phase 1 districts. Health centre staff assist with identify-
ing children who may meet eligibility criteria. Healthy
children presenting for routine check-up aged 5–8 weeks
and 12–23months whose families have lived in the area
for at least three consecutive months are eligible. Any
child who has a temperature of > 37 °C per axilla is ex-
cluded. Study nurses explain the study purpose to the
parent or guardian, verify eligibility, obtain informed
consent and collect the information and swab from chil-
dren for whom consent is given.
Sample size
A sample size of 281 in each survey has 90% power at a
5% significance level to show ~ 50% reduction in VT car-
riage prevalence (16 to 8%). As the true prevalence of
VT carriage in this population is unknown, the sample
size for each survey has been increased to 500 in the 5–
8 weeks old infants and 500 for the 12–23month group.
Statistical analysis
The prevalence of VT, NVT and all pneumococcal car-
riage will be documented for both age cohorts, broken
down by year and, where possible, PCV13 vaccination
status. Comparisons of median ages and other quantita-
tive measures of participant characteristics from year to
year, and by PCV13 vaccination status will be made
using Wilcoxon rank-sum tests. Comparisons of sex,
ethnic group distribution, and other categorical variables
will be made using a Chi-square test. To examine the
impact of PCV13 on carriage, we will calculate preva-
lence ratios that compare carriage in the pre-vaccine
period with carriage in the first and final post-vaccine
survey. To account for potential confounders, adjusted
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prevalence ratios will be calculated using log-binomial
regression.
Current status
The study is ongoing and expected to continue to 2020.
Data analysis with publication of results is anticipated
from 2019. As of 1st May 2018, we have enrolled 11,010
eligible cases into the study since start-up. Table 3
shows the baseline characteristics of children re-
cruited to May 2018.
Discussion
Establishing a robust surveillance system is an important
component of monitoring the impact of PCV within a
country. The enhanced surveillance system in Mongolia
will facilitate the assessment of PCV13 impact on
pneumonia, with radiological confirmed disease as the
primary outcome. Establishing the surveillance system
was not without its challenges, but the lessons
learned in addressing these challenges may be of rele-
vance to other countries seeking to establish surveil-
lance for pneumonia.
There have been four key lessons learned thus far. The
first lesson has been the importance of establishing a
core group of hospital staff at each site to be responsible
for the surveillance activities, and for the PCV impact
evaluation team to work closely and collaboratively with
each hospital surveillance team. The hospital teams
should be active partners in the evaluation activity. Such
partnership supports the collection of high quality data
and ensures that any problems can be identified and ad-
dressed rapidly. The winter of 2015/16 in Mongolia was
very severe, and hospitals were finding it difficult to
manage surveillance enrolment with such a high patient
load. In some hospitals, staff from other wards were
brought in to relieve the burden in the admissions and
paediatric wards, but several of these staff had not been
trained on how to enrol patients into the surveillance
system. It was not until later, when we reviewed the de-
clining enrolment rate, that these issues were identified.
We have since increased our focus on having more regu-
lar engagement with hospital teams and actively encour-
age teams to share with us their experiences in
implementing the surveillance.
The second lesson is that a number of external factors
can potentially influence disease burden estimates, by in-
fluencing the volume of patients presenting to hospital
and their severity of disease. It is necessary to maintain
awareness of such factors, and to implement strategies
to be able to quantify any impact on surveillance-related
outcomes. A significant external factor we have identi-
fied in this study is a change in referral practice. When
our enhanced surveillance commenced, antibiotics in-
cluded in the IMCI algorithms were available free-of-
charge for inpatients only. In 2016, these antibiotics be-
came available at no cost for outpatients presenting to
Family Health Centres, which almost certainly would
have resulted in a larger proportion of patients being
treated as outpatients rather than being referred to hos-
pital. Similarly, the 2013 revision of the WHO IMCI
guidelines for the management of acute respiratory in-
fection (removing chest indrawing as a sign of severe
pneumonia requiring hospitalisation) was formally
adopted in Mongolia in 2015. The adoption of these re-
vised guidelines during the evaluation period would
likely result in a reduction in the number of patients be-
ing referred for hospital care. The effect of these changes
will be reviewed. Having mechanisms that enable regular
communication and cooperation with key agencies, both
within and outside of health, can help to ensure that po-
tential external factors are identified.
The third lesson is that flexibility in data collection
and processes is also necessary, in order to respond to
changing circumstances. During 2015–2016 there was a
large outbreak of measles in Mongolia. Cases emerged
from March 2015, and by the end of that year it ap-
peared that the epidemic was ending; however, in early
2016 there was a major resurgence that continued until
July. As measles substantially increases the risk of pneu-
monia [41], there is potential for this outbreak to result
in an increase in pneumonia cases, thus complicating
our measurement of PCV13 impact. To be able to quan-
tify the number of potentially measles-associated pneu-
monia cases being captured in the surveillance system, it
was necessary to modify the CRFs and conduct a train-
ing update with hospital staff in order to collect data on
the measles history of each surveillance case.
The fourth lesson is to ensure a consistent application
of the pneumonia surveillance case definition. It is
Table 3 Baseline characteristics of cases enrolled into pneumonia
surveillance programme, Mongolia, 2015–2018 (N = 11,010)
n (%)
Year of recruitment 2015a 1901 (17)
2016 4025 (37)
2017 3533 (32)
2018b 1551 (14)
Age group < 12 months 4107 (37)
12–23months 3376 (31)
24–59months 3527 (32)
Gender Male 5914 (54)
District Songinokhairkhan 2975 (27)
Sukhbaatar 2350 (21)
Bayanzurkh 3413 (31)
Chingeltei 2272 (21)
aFrom 1st April 2015; bTo 1st May 2018
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challenging to develop and apply a clear case definition
that achieves a balance between capturing all cases that
are likely true pneumonia, without overloading doctors
with enrolment of all patients with acute respiratory in-
fection, the most common cause of hospital admission
for children in Mongolia and much of the world. A re-
view of the existing IB-VPD surveillance system in early
2015, just prior to the commencement of enhanced sur-
veillance, identified the problem of under-enrolment.
Consultation with hospital staff identified a lack of clar-
ity in the surveillance case definitions. In some hospitals,
suspected pneumonia cases reporting prior antibiotic
use (e.g. at home) prior to admission were also being ex-
cluded unnecessarily from the surveillance system (prior
antibiotic use is recorded on the CRF, but not an exclu-
sion criterion). In liaison with the Ministry of Health
and WHO, the surveillance case definition was updated
to be more specific (thus reducing the number of eligible
cases and consequently the case load for admitting doc-
tors). While this was an important step to ensure all
cases could be captured, a shortcoming of this change to
the definition is that it will be more difficult to compare
results of impact on clinical pneumonia with those from
the earlier clinical trials. To ensure that all hospital staff
were using the correct case definition and maintain
consistency in enrolment from the start of the enhanced
surveillance, refresher training in the case definition was
conducted in all hospitals. A number of printed re-
sources were produced to assist hospital staff in correct
application of the simplified surveillance case definition
and to ensure that all necessary surveillance data are
collected. This included a wall poster to be placed in the
relevant areas in the hospitals, and easy-reference pocket
guides to be carried by the doctors. The weekly enrol-
ment rate monitoring system described above was also
established. Frequent staff turnover in hospitals presents
the need for frequent re-training, both in the case defin-
ition and in surveillance procedures. Strategies that we
have implemented to meet this need for ongoing train-
ing include the train-the-trainer approach and produc-
tion of short instructional videos.
Given the concern about correct application of the
case definition and cases being missed, to ensure
complete ascertainment of eligible cases for the first year
of enhanced surveillance, a medical record review of all
age-eligible pneumonia admissions to the 5 participating
hospitals has been undertaken for the first year of
enhanced surveillance. The culture of detailed medical
record keeping in Mongolia has allowed us to retro-
spectively capture the majority of data from missed cases
through review of their patient file, though unfortunately
with the notable absence of radiology data. In addition a
retrospective review will also be done for all pneumonia
cases in children < 5 years from April 2013 to March
2015, and all empyema cases in children < 5 years from
April 2010 to March 2015.
Radiological pneumonia has been shown to be the best
pneumonia endpoint for pneumococcal disease [15–18].
Radiology is therefore central to this evaluation, but it is
an area in which many resource-constrained settings
have limited scope to produce reliable, high quality data.
In establishing the data collection systems for this evalu-
ation, the PCV impact evaluation team worked very
closely with hospital radiology departments to strengthen
and support their systems, equipment and capacity. A
comprehensive audit of equipment and processes as well
as training was done prior to start-up of enrolment. These
actions and the ongoing weekly quality assurance checks,
has resulted in the production of high quality radiologic
films for the study. Fewer than 3% of the 3100 films that
had been re-read by the end of 2016 were uninterpretable
for endpoint consolidation. This is a lower proportion
than that reported in the PERCH study (10%) [42]. Ensur-
ing adequate resources are available for ongoing radiology
equipment maintenance and repair should be considered
in developing evaluation budgets.
Virology testing is a novel aspect of this evaluation
project because the clinical evidence in the context of
pre- and post-PCV introduction is still limited. The in-
formation provided from this study will be critical not
only for Mongolia but for many other countries as RSV
is a leading pathogen in paediatric LRTI worldwide.
These data will also provide a valuable baseline of sea-
sonal, epidemiological burden of RSV and influenza in-
fections in children less than 2 years of age with severe
pneumonia. This will complement data collected by the
Ministry of Health and WHO RSV surveillance system,
which began in May 2017 as part of the influenza-like
illness programme and detects milder cases of RSV in all
age groups. Moreover, laboratory capacity building on
RSV and influenza testing derived from this project has
provided the NCCD Virology Laboratory with additional
RNA extraction and qPCR machines and a higher cap-
acity to deal with the high volume of samples derived
from the project, as well as routine testing, and from the
RSV and influenza surveillance. Following each qPCR
run, results are loaded into a cloud account that can be
accessed by all collaborators. The surveillance may have
missed some children with RSV as the enhanced sur-
veillance system did not enrol children with bronchio-
litis and the oxygen cut-off was lower than that used
for RSV [29].
While pneumococcal nasopharyngeal carriage is a pre-
cursor to pneumococcal disease, the interplay between
the presence of pneumococci in the nasopharynx and
pneumonia is poorly understood. High pneumococcal
density (8000 copies/ml) from nasopharyngeal swabs has
been shown to have high diagnostic accuracy in
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diagnosing pneumococcal pneumonia in adults [43]. In
children, pneumococcal density in the nasopharynx is
higher in children with radiological pneumonia com-
pared to healthy controls or children with milder re-
spiratory tract infection [44]. Nasopharyngeal swab
analysis of pneumonia cases provide important informa-
tion on likely pneumonia aetiology as well as additional
information on the circulating serotypes in a population,
and can assist in monitoring the direct and indirect ef-
fects of PCV13 introduction. To assess pneumococcal
carriage we have applied gold-standard microbiological
approaches. However, this strategy was also selected as
the laboratory flow is relatively ‘modular’ facilitating
strengthening of key assays such as lytA qPCR to sup-
port on-going surveillance, using the same DNA extrac-
tion and real-time PCR platforms as the virology assays.
A phased strategy for long-term technology transfer has
been developed with the project partners, and will con-
tinue to evolve as the project progresses. To date, activ-
ities have included a joint visit from the MCRI and
IB-VPD microbiologist, an MCRI only visit and a la-
boratory training visit at MCRI for two NCCD la-
boratory personnel.
Finally, it is important to put mechanisms in place to
ensure that the expanded surveillance and key laboratory
capacity provided through the funded project can be
sustained. For example, in the case of radiology, equip-
ment was provided to some sites to enable the digitisa-
tion of x-rays. This is essential for the evaluation, as it
enables the electronic archiving and transfer of images
for re-reading and for archiving project data. In sites
where this equipment could not be supplied, the project
meets the cost of the x-ray film and printing reagents
and an x-ray scanner is used to produce an electronic
copy. However, in most hospitals there is no internal
network that allows doctors to view the image on a com-
puter elsewhere in the hospital, so it is impractical to
only have an electronic copy of the radiograph. Without
this internal network capability, and with very limited
funds for printing x-rays, there is a risk that hospitals
will revert to the earlier practice of fluoroscopy, the
equipment provided will fall into disuse and the capacity
that has been built among the local radiology teams to
use the equipment will be lost. However, with the
strengthened capacity for clinical research and surveil-
lance created in country, due to exposure and participa-
tion of hospital staff, as well as the buy-in of the
Ministry of Health to continue with the surveillance fol-
lowing the donor funding period, there is commitment
to ensure that the programme is maintained.
Our study has a number of strengths. Firstly the
methods used are consistent with other international re-
search activities studying nasopharyngeal carriage, in-
cluding studies undertaken by our group in Lao PDR
and Fiji [45–47]. Secondly we used sensitive gold-standard
molecular methods to detect pneumococcus in the naso-
pharynx. Our method of microarray with a culture ampli-
fication step was the top-performing method in a large,
international multi-centre study exploring the best
pneumococcal serotyping methods for carriage studies
[31], and will provide density data to the level of serotype.
Thirdly, the identification of radiological pneumonia cases
that have an elevated CRP [48], and have either heavy
nasopharyngeal carriage, or carriage of pneumonia-associ-
ated serotypes, will identify a subgroup that is more likely
to be pneumococcal in origin and may thus be expected
to decline in incidence more sharply than the total radio-
logical incidence with the introduction of an effective
PCV. Fourthly, our community carriage surveys include
children too young to be vaccinated (5–8 weeks of age).
This allows us to document the herd immunity in very
young infants who are at high risk of pneumococcal dis-
ease, especially meningitis.
Conclusion
The PCV impact evaluation in Mongolia will provide
data to help guide national vaccine policy, and contrib-
ute to the limited evidence base on the burden of
pneumococcal pneumonia in LMICs, particularly in
Asia. In addition, it provides one of the first experiences
of implementing prospective, population-based pneumo-
nia surveillance to evaluate the impact of PCV in a
resource-limited setting. With increasing introduction of
PCV in these settings, the methods, experiences and les-
sons learned from this activity may be used to guide the
development of such systems in other areas.
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